leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...209210211212213214215216217218219...235236»
  • ||||||||||  Zaltrap (ziv-aflibercept IV) / Sanofi
    Trial primary completion date, HEOR, Combination therapy, Metastases:  AFEQT: Colorectal Cancer Metastatic (clinicaltrials.gov) -  Mar 14, 2015   
    P3,  N=200, Active, not recruiting, 
    Trial primary completion date: Dec 2014 --> Apr 2015
  • ||||||||||  Biomarker, Trial initiation date, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker:  MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) -  Mar 10, 2015   
    P2,  N=610, Not yet recruiting, 
    Recruiting --> Completed | Trial primary completion date: Jan 2012 --> Oct 2011 Initiation date: Jan 2015 --> Apr 2015 | Trial primary completion date: Nov 2020 --> May 2019
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial primary completion date:  RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma (clinicaltrials.gov) -  Mar 5, 2015   
    P1/2,  N=45, Active, not recruiting, 
    Trial primary completion date: Jul 2015 --> Oct 2015 Trial primary completion date: Jan 2015 --> Jan 2017
  • ||||||||||  leucovorin calcium / Generic mfg.
    Trial primary completion date:  A Folinic Acid Intervention for Autism Spectrum Disorders (clinicaltrials.gov) -  Mar 3, 2015   
    P2,  N=192, Recruiting, 
    Trial primary completion date: Jan 2015 --> Jan 2017 Trial primary completion date: Sep 2015 --> Sep 2017
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Enrollment change, Trial termination, Trial primary completion date:  Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer (clinicaltrials.gov) -  Mar 3, 2015   
    P2,  N=2, Terminated, 
    Trial primary completion date: Sep 2015 --> Sep 2017 N=14 --> 2 | Recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Jul 2014; PI Decision
  • ||||||||||  conatumumab (AMG 655) / Amgen
    Enrollment closed, Trial primary completion date:  Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) -  Feb 20, 2015   
    P2,  N=12, Active, not recruiting, 
    N=240 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Apr 2015
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Trial primary completion date, Metastases:  Phase I Trial of Combination of FOLFIRI and SOM 230 (clinicaltrials.gov) -  Feb 6, 2015   
    P1,  N=16, Active, not recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Aug 2015 --> Dec 2015
  • ||||||||||  Enrollment closed, Trial primary completion date, Metastases:  FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) -  Feb 2, 2015   
    P2,  N=45, Active, not recruiting, 
    Trial primary completion date: Jul 2014 --> Jul 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jan 2016
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly
    Enrollment change, Trial termination, Metastases:  Colorectal Cancer (CRC) Cetuximab Elderly Frail (clinicaltrials.gov) -  Jan 28, 2015   
    P2,  N=5, Terminated, 
    Trial primary completion date: Aug 2014 --> Aug 2015 N=150 --> 5 | Recruiting --> Terminated; poor accrual